Skip to main content
A

Ananda Pharma Plc — Investor Relations & Filings

Ticker · ANAN ISIN · GB00BDQPXQ60 LEI · 894500DFM8VOC5FW4X47 Aquis Stock Exchange Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2025-02-21 Regulatory Filings
Country GB United Kingdom
Listing Aquis Stock Exchange ANAN

About Ananda Pharma Plc

https://www.anandapharma.co.uk/

Ananda Pharma Plc is a biopharmaceutical company focused on the development of regulatory-approved, cannabinoid-based medicines. The company's primary mission is to create therapies for complex, chronic inflammatory conditions with significant unmet medical needs. Its development pipeline is initially centered on treatments for inflammatory pain conditions, including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and endometriosis, as well as heart failure with preserved ejection fraction (HFpEF). Ananda Pharma's approach covers the full development cycle, from identifying clinical potential and optimizing drug candidates to conducting clinical trials and securing marketing authorizations from regulators.

Recent filings

Filing Released Lang Actions
CEO Presenting at Private Investor Conference
Regulatory Filings Classification · 95% confidence The document is a press release distributed via the London Stock Exchange's RNS (Reach) service. It announces that the CEO of Ananda Pharma PLC is presenting at a private investor conference in Zurich. This does not constitute a formal financial report, proxy, or governance document, but rather a corporate announcement regarding company activities and investor relations. As it does not fit into specific categories like M&A, dividends, or share issues, it falls under the general regulatory announcement category.
2025-02-21 English
Achievement of Manufacturing Milestone for MRX1
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement (RNS) issued by Ananda Pharma PLC regarding a specific operational milestone: the completion of a manufacturing batch for their MRX1 drug candidate. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general corporate update regarding business operations and regulatory progress, it falls under the 'Regulatory Filings' (RNS) category.
2025-02-20 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official announcement regarding a share purchase by the company's Chief Executive Officer, Melissa Sturgess. It explicitly includes the 'Director/PDMR Shareholding' header and a detailed 'Market Abuse Regulation (MAR) Disclosure' table, which is the standard format for reporting insider transactions by persons discharging managerial responsibilities. This fits the definition of a Director's Dealing (DIRS) filing.
2025-02-06 English
Appointment of Commercial Adviser
Board/Management Information Classification · 95% confidence The document is an official announcement from Ananda Pharma PLC regarding the appointment of a new commercial adviser, Andy Rust. It is distributed via the RNS (Regulatory News Service) platform. Since it pertains to a change in management/advisory personnel rather than a financial report, dividend, or share transaction, it falls under the category of general regulatory announcements or corporate updates. Given the specific nature of the announcement (appointment of personnel), it fits best as a general regulatory filing (RNS) as it does not meet the criteria for a board director change (MANG) specifically, but rather an advisory role.
2025-02-06 English
Change of Registered Office
Regulatory Filings Classification · 98% confidence The document is a short regulatory announcement (RNS) regarding a change of the company's registered office address. It does not fit into specific categories like financial reports, board changes, or share transactions. As it is a general corporate update provided via the London Stock Exchange's RNS service, it falls under the fallback category for regulatory announcements.
2025-02-03 English
Ananda Pharma Appoints Viridian Capital Advisors
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces the appointment of a new advisory firm (Viridian Capital Advisors) to assist with U.S. market strategy. Since it does not fit into specific categories like M&A, Board changes, or financial reporting, and is a general corporate announcement distributed via a regulatory channel, it is classified as a Regulatory Filing (RNS).
2025-02-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.